Interpreting and Applying New Data in Multiple Myeloma: Strategies for Improving Patient Care

Activity Description & Educational Objectives

In this activity, an expert panel on multiple myeloma discusses the clinical importance of recent data on myeloma management across treatment settings. The panel will review findings of note in transplant-eligible and -ineligible populations and will tie relevant findings to clinical decision making. In addition, the panel will address how new data on emerging and established therapy may be used to optimize care for patients with relapsed/refractory disease.

Upon completion of this activity, participants will be able to:

• Identify and/or apply new findings on optimized primary therapy for transplant-eligible or -ineligible patients with multiple myeloma
• Employ validated maintenance strategies in eligible patients with myeloma after primary therapy or stem cell transplant
• Select personalized therapy for patients with relapsed/refractory myeloma based on key safety and efficacy data and prior treatment history
• Cite and/or utilize novel therapeutics appropriate for patients with relapsed disease, including consideration of clinical trial-based therapy for eligible individuals

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, nurses, and other professionals engaged in the management of patients with multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: July 17, 2012 - July 16, 2013
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Paul Richardson, MD, PhD
Clinical Director, Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts

Paul Richardson, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Advisory Board for Bristol-Myers Squibb; Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Keryx Biopharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Nereus Pharmaceuticals; and Novartis Pharmaceuticals Corporation.

Interviewees

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Sagar Lonial, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Bristol-Myers Squibb; Celgene Corporation; Merck & Co. Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Robert Z. Orlowski, MD, PhD
Professor of Medicine
Department of Lymphoma/Myeloma and
Experimental Therapeutics
MD Anderson Cancer Center
Houston, Texas

Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; and Millennium: The Takeda Oncology Company.

Advisory Board for Bristol-Myers Squibb; Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5126-12-T.

Nurses

IAHB is an approved provider of continuing nursing education by the Utah Nurses Association, an accredited Approver by the American Nurses Credentialing Center’s Commission on Accreditation. (UNA = 1.0 CEH's. Provider Code P09-03).

This CME/CNE activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; the activity is also co-provided by the Institute for Advancement of Human Behavior.

This activity is supported by educational grants from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.